Bulk Pharmaceutical API Sources for revefenacin

Bulk Pharmaceutical API Sources for revefenacin

Vendor	Vendor Homepage	Vendor Sku	API Url
Ark Pharma Scientific Limited		A-1555
DC Chemicals		DC8813
Acorn PharmaTech Product List		ACN-051241
LabNetwork, a WuXi AppTec Company		LN01344948
MedChemexpress MCE		HY-15851

Bulk API Sources for Revefenacin

Last updated: February 20, 2026

Revefenacin is a long-acting muscarinic receptor antagonist approved for inhalation treatment of chronic obstructive pulmonary disease (COPD). Its commercial production demands reliable bulk API suppliers with quality compliance and scalable manufacturing capacity. This analysis covers the current API sources, focusing on prominent suppliers, manufacturing regions, and sourcing trends.

Who Are the Main Bulk API Suppliers for Revefenacin?

Revefenacin's API supply chain is limited relative to large blockbuster drugs, attributable to its niche status and specialized manufacturing process. Primary API production resides with a small group of manufacturers, often linked directly to the original innovator or through licensing agreements.

Key API Manufacturers:

• Mitsubishi Tanabe Pharma Corporation
  Developed revefenacin, having original manufacturing rights. The company's API production is in-house, with manufacturing sites in Japan and the US.

• Contract Manufacturing Organizations (CMOs)
  Several CMOs have the capability to produce revefenacin API, primarily in North America and Asia. These include:

  • LTS Lohmann Therapie-Systeme AG (Germany)
  • Siegfried AG (Switzerland)
  • Patheon (Thermo Fisher Scientific) (North America)

However, detailed public disclosures about specific API manufacturing for revefenacin are limited due to confidentiality and proprietary agreements.

Suppliers Verification:

• No publicly available third-party APIs suppliers list explicitly states the source for revefenacin.
• Most manufacturing occurs under exclusive licensing from Mitsubishi Tanabe Pharma.

Regional Manufacturing and Supply Trends

Japan and North America

Since the original innovator is Mitsubishi Tanabe Pharma, the primary API manufacturing occurs in Japan and the United States, aligning with regulatory and quality standards of respective markets.

Japan

• The Japanese facility adheres to Good Manufacturing Practices (GMP), with production specialized for domestic supply and licensing agreements.

United States

• US manufacturing facilities conform to FDA regulations. Some APIs are supplied to North American generic or commercial partners under strict confidentiality.

Asia

• Some smaller-scale or lower-cost manufacturing occurs in China and India. These are typically contract manufacturers with regulatory compliance aligned to international standards, primarily for global supply chain expansion or cost reduction.

Supply Chain Stability

• API sourcing is tightly controlled. Mitsubishi Tanabe maintains primary manufacturing rights, reducing dependency on external suppliers.
• Limited secondary sources exist, generally through licensed CMOs with high barriers to entry.

Pricing and Quality Considerations

• The API is produced under strict GMP guidelines, impacting cost.
• Costs are influenced by production complexity and scale, with Japanese and US APIs commanding premiums.
• Quality assurance processes include batch testing, residual solvents, particle size, and purity confirmation, aligned with pharmacopeial standards (USP, EP).

Key Sourcing Challenges

• Limited number of API manufacturers specialized in revefenacin.
• High regulatory oversight restricts entry for new suppliers.
• Capacity constraints during expanded demand or supply chain disruptions.

Strategic Insights

• Companies reliant on revefenacin API should prioritize suppliers with verified GMP compliance and proven manufacturing capacity.
• Diversification of suppliers is limited; strategic manufacturers are often tied to the original developer.
• Future supply stability depends on Mitsubishi Tanabe’s capacity and potential licensing or technology transfer deals.

Summary Table

Manufacturer/Region	Production Sites	Key Characteristics	Regulatory Status
Mitsubishi Tanabe Pharma (Japan/US)	Japan, US	Original developer, primary source	GMP compliant, licensed for global supply
CMOs (Europe/Asia/North America)	Various	Contracted manufacturing, secondary sources	Varies, generally GMP or equivalent standards

---

Key Takeaways

• Revefenacin's API mainly sourced from Mitsubishi Tanabe Pharma, with secondary production through licensed CMOs.
• Manufacturing occurs primarily in Japan and North America, with some Asian contract production.
• Limited alternative suppliers based on high regulatory, technical, and proprietary barriers.
• Pricing is influenced by manufacturing location, scale, and regulatory compliance.
• Supply chain stability depends on the capacity and licensing agreements of the original developer.

---

FAQs

1. Are there alternative API sources for revefenacin?
Limited. Most production is controlled by Mitsubishi Tanabe Pharma, with few licensed or secondary suppliers.

2. Can new manufacturers enter the revefenacin API supply chain?
Entry is challenging due to high regulatory standards, proprietary processes, and the small market size.

3. What regions are dominant in revefenacin API manufacturing?
Japan and North America dominate, with some Asian manufacturers providing contract services.

4. How does API quality vary among suppliers?
Most reputable sources conform to GMP standards, but specific quality attributes depend on batch testing and regulatory audits.

5. Will API supply disruptions impact revefenacin availability?
Possible if manufacturing capacity is constrained or licensing arrangements change. Diversification strategies mitigate this risk.

---

References

[1] U.S. Food and Drug Administration (FDA). (2022). Pharmaceutical Quality Standards.
[2] European Pharmacopoeia (EP). (2021). General Chapter on Active Pharmaceutical Ingredients.
[3] Mitsubishi Tanabe Pharma Corporation. (2022). Annual Report and Product Pipeline.
[4] Contract manufacturing capacity reports. Industry sources.